# A Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator's Choice of Standard of Care Therapy, in Patients With Coronavirus Disease 19 (COVID-19)

> **NCT04379271** · PHASE2,PHASE3 · COMPLETED · sponsor: **Immunic AG** · enrollment: 234 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** IMU-838
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04379271
- **Lead sponsor:** Immunic AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-11
- **Primary completion:** 2021-01-12
- **Final completion:** 2021-02-23
- **Target enrollment:** 234 (ACTUAL)
- **Last updated:** 2024-11-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04379271

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04379271, "A Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator's Choice of Standard of Care Therapy, in Patients With Coronavirus Disease 19 (COVID-19)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04379271. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*